NCT04691947View on ClinicalTrials.gov

Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

November 18, 2021

Study Completion Date

November 18, 2021

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

ERUCOV-VAC

Vaccination on Day 0 and Day 21

OTHER

Placebo Vaccine

Placebo Vaccination on Day 0 and Day 21

Trial Locations (1)

38038

Erciyes University Hakan Çetinsaya Iyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP), Kayseri

All Listed Sponsors
collaborator

TC Erciyes University

OTHER

lead

Health Institutes of Turkey

OTHER_GOV

NCT04691947 - Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC | Biotech Hunter | Biotech Hunter